共 121 条
[1]
Garland SG(2019)Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention Ann Pharmacother 53 933-939
[2]
Smith SM(2021)Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis Front Pharmacol 12 649143-404
[3]
Gums JG(2021)CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs J Headache Pain. 22 128-701
[4]
Wang X(2019)How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective Curr Opin Neurol 32 395-372
[5]
Chen Y(2018)Precision medicine: from science to value Health Aff (Millwood) 37 694-202
[6]
Song J(2021)Erenumab in the prevention of high-frequency episodic and chronic migraine: EARLY (ErenumAb in real life in ItalY), the first Italian multicenter, prospective real-life study Headache. 61 363-808
[7]
You C(2021)GalcanezumAb for the prevention of high frequency episodic and chronic migraine in real life in ITaly: a multicenter prospective cohort study (the GARLIT study) J Headache Pain. 22 35-1340
[8]
Vandervorst F(2021)Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study J Headache Pain. 22 114-307
[9]
Van Deun L(2021)Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months J Headache Pain. 22 120-634
[10]
Van Dycke A(2022)Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score CNS Drugs 36 191-102